“They’re not shortcuts”: How weight loss drugs became the business of shame
As New Year’s resolutions kick into high gear, weight loss goals top many people’s lists. Like clockwork, advertisements for weight loss programs and supplements are popping up on social media, ready to pounce on the demand. The weight loss drug market is exploding, with new products entering the scene to compete with big names like Ozempic. It is no surprise, considering the millions of people worldwide struggling with obesity, PCOS and diabetes. The medications’ promise of weight loss without a complete lifestyle overhaul has sparked hope and controversy, and the market shows no signs of slowing down. Ozempic, Wegovy, Mounjaro and other GLP-1 drugs have transformed how obesity is treated and have corresponded with a 25% decrease in weight-loss surgeries. Sixteen new drugs are set to enter the market in the coming years, per Reuters, and analysts estimate the overall market could expand to $200 billion by 2031. There’s an ongoing debate about how GLP-1 drugs fit into a comprehensive strategy for managing obesity, their potential side effects and costs. The growing market also has revealed societal …